Key result
No clinical data or abstract is available for this letter discussing enoxaparin in unstable ischemic heart disease.
Answers are grounded in this paper and cite their sources.
Does not alter unstable ischemic heart disease management; leaves open enoxaparin's role pending controlled data.
Letters| July 19 2002 Enoxaparin in Unstable Ischemic Heart Disease: Friend or Foe? Subject Area: Cardiovascular System Augustine T.M. Tang; Augustine T.M. Tang Departments of Cardiac Surgery and Search for other works by this author on: This Site PubMed Google Scholar Paul R. Kalra; Paul R. Kalra Cardiology, Southampton General Hospital, Southampton, UK Search for other works by this author on: This Site PubMed Google Scholar Alison L. Calver; Alison L. Calver Cardiology, Southampton General Hospital, Southampton, UK Search for other works by this author on: This Site PubMed Google Scholar James L. Monro James L. Monro Departments of Cardiac Surgery and Search for other works by this author on: This Site PubMed Google Scholar Cardiology (2002) 97 (4): 236–237. https://doi.org/10.1159/000063117 Article history Received: November 24 2001 Accepted: February 16 2002 Published Online: July 19 2002 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Augustine T.M. Tang, Paul R. Kalra, Alison L. Calver, James L. Monro; Enoxaparin in Unstable Ischemic Heart Disease: Friend or Foe?. Cardiology 1 July 2002; 97 (4): 236–237. https://doi.org/10.1159/000063117 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsCardiology Search Advanced Search This content is only available via PDF. 2002Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2002) conducted a letter in Unstable Ischemic Heart Disease. Enoxaparin was evaluated. No clinical data or abstract is available for this letter discussing enoxaparin in unstable ischemic heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: